TP53 and prostate carcinoma: Since more than one third of prostate cancers harbor mutant p53[27,28] and majority of prostate cancers also lack Id4[18,19]; hence physiological mechanisms involved in the transition of mutant p53 to wild type activity are of clinical relevance.